Assessing The Impact Of Incorporating Charlson Comorbidity Scores On Patient Anxiety And Satisfaction

Benaroya Research Institute

Status: Completed

Conditions: Prostate Cancer

Treatments: Other: Prostate Cancer Comorbidity Index (PCCI) score

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT03950180

IRB13054

Details and patient eligibility

About

The purpose of this study was to determine whether providing patients with life expectancy (LE) information in the form of their Prostate Cancer Comorbidity Index (PCCI) scores impacted their decisional conflict or anxiety about prostate cancer or death.

Full description

Patients with newly diagnosed prostate cancer were consented and randomized to receive standard of care counseling (SOC) versus the same counseling plus provision of their specific LE (PCCI). Patients were blinded to the specific content of their counseling session. After counseling, patients completed the Decisional Conflict Scale (DCS), Death Anxiety Scale (DAS), Memorial Anxiety Scale for Prostate Cancer (MAX-PC), and Patient Satisfaction Questionnaire (PSQ-18). Treatment preferences were assessed.

Enrollment: 277 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Men 18 years and older
• Newly diagnosed prostate cancer

Exclusion criteria

• Non-English speaking
• Prior history of prostate cancer

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

277 participants in 2 patient groups

PCCI group

Active Comparator group

Description:

In addition to standard of care counseling the additional provision of the patient's specific Prostate Cancer Comorbidity Index score and life expectancy estimation was provided.

Treatment:

Other: Prostate Cancer Comorbidity Index (PCCI) score

Standard care

No Intervention group

Description:

Standard of care was defined as prostate cancer counseling reflecting the best practices of a multidisciplinary team of urologists, radiation oncologists and medical oncologists.